Referencias►
1.
Gaddi A, Descovich GC, Noseda G, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia.
Atherosclerosis. 1984;50:73 - 83.
2.
Angelico M, Pinto G, Ciaccheri C, et al. Improvement in serum lipid profile in hyperlipoproteinaemic patients after treatment with pantethine: a crossover, double-blind trial versus placebo.
Curr Ther Res. 1983;33:1091-1097.
3.
Bertolini S, Donati C, Elicio N, et al. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children.
Int J Clin Pharmacol Ther Toxicol. 1986;24:630 - 637.
4.
Arsenio L, Caronna S, Lateana M, et al. Hyperlipidemia, diabetes and atherosclerosis: Efficacy of treatment with pantethine [in Italian, English abstract].
Acta Biomed Ateneo Parmense. 1984;55:25 - 42.
5.
Donati C, Barbi G, Cairo G, et al. Pantethine improves the lipid abnormalities of chronic hemodialysis patients: Results of a multicenter clinical trial.
Clin Nephrol. 1986;25:70 - 74.
6.
Donati C, Bertieri RS, Barbi G. Pantethine, diabetes mellitus and atherosclerosis. Clinical study of 1045 patients [in Italian, English abstract].
Clin Ter. 1989;128:411 - 422.
7.
Coronel G, Tornero F, Torrente J, et al. Treatment of hyperlipidemia in diabetic patients on dialysis with a physiological substance.
Am J Nephrol. 1991;11:32 - 36.
8.
[No authors listed]. Calcium pantothenate in arthritic conditions. A report from the General Practitioner Research Group.
Practitioner.
1980;224:208 - 211.
9.
Barton-Wright EC, Elliott WA. The pantothenic acid metabolism of rheumatoid arthritis.
Lancet.
1963;2:862 - 863.
10.
Gaddi A, Descovich GC, Noseda G, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia.
Atherosclerosis. 1984;50:73 - 83.
11.
Angelico M, Pinto G, Ciaccheri C, et al. Improvement in serum lipid profile in hyperlipoproteinaemic patients after treatment with pantethine: a crossover, double-blind trial versus placebo.
Curr Ther Res. 1983;33:1091-1097.
12.
Bertolini S, Donati C, Elicio N, et al. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children.
Int J Clin Pharmacol Ther Toxicol. 1986;24:630 - 637.
13.
Gaddi A, Descovich GC, Noseda G, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia.
Atherosclerosis. 1984;50:73 - 83.
14.
Rubba R, Postiglione A, De Simone B, et al. Comparative evaluation of the lipid-lowering effects of fenofibrate and pantethine in type II hyperlipoproteinemia.
Curr Ther Res. 1985;38:719 - 727.
15.
Da Col PG, Cattin L, Fonda M, et al. Pantethine in the treatment of hypercholesterolemia: a randomized double-blind trial versus tiadenol.
Curr Ther Res.
1984;36:314 - 322.
16.
Arsenio L, Caronna S, Lateana M, et al. Hyperlipidemia, diabetes and atherosclerosis: Efficacy of treatment with pantethine [in Italian, English abstract].
Acta Biomed Ateneo Parmense. 1984;55:25 - 42.
17.
Donati C, Barbi G, Cairo G, et al. Pantethine improves the lipid abnormalities of chronic hemodialysis patients: Results of a multicenter clinical trial.
Clin Nephrol. 1986;25:70 - 74.
18.
Donati C, Bertieri RS, Barbi G. Pantethine, diabetes mellitus and atherosclerosis. Clinical study of 1045 patients [in Italian, English abstract].
Clin Ter. 1989;128:411 - 422.
19.
Coronel G, Tornero F, Torrente J, et al. Treatment of hyperlipidemia in diabetic patients on dialysis with a physiological substance.
Am J Nephrol. 1991;11:32 - 36.
20.
Carrara P, Matturri L, Galbussera M, et al. Pantethine reduces plasma cholesterol and the severity of arterial lesions in experimental hypercholesterolemic rabbits.
Atherosclerosis. 1984;53:255 - 264.
21.
Barton-Wright EC, Elliott WA. The pantothenic acid metabolism of rheumatoid arthritis.
Lancet.
1963;2:862 - 863.
22.
[No authors listed]. Calcium pantothenate in arthritic conditions. A report from the General Practitioner Research Group.
Practitioner.
1980;224:208 - 211.